Board summary
Key figures
49,060
Registered population
59.9% aged 18–64
23.0%
Aged 65+
ICB 21.9% · England 17.9%
8.9%
Ethnic minority (non-White)
4.1% Asian · England 9.6%
6.2%
In IMD quintile 1
ICB 9.2% · England 21.0%
~2,895
Core20 residents (est.)
Resident basis; registered basis ~3,053 · see page 3
8,485
Hypertension register
+1.97% in 3 yrs · England +5.60%
788
SMI register
49.2% of Worthing's
905
COPD register
Reviews -1.65% in 3 yrs
Forecast to 2030
9,027
Hypertension patients, 2030
+542 on today
67.1%
QRISK ≥20% on statins, 2030
+5.63pp over 3 yrs
5.7%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
High-risk lipid therapy and elderly BP lag England.
Despite +11.7% three-year growth, QRISK ≥ 20% lipid therapy (53.8% vs 63.6% in England) and aged 80+ BP control (73.4% vs 81.2%) trail national.
Sixteen of 25 three-year changes trail England.
Reviews fell over 2023 to 2025 for heart failure (-2.3%), psychosis alcohol (-3.5 pp) and asthma (-1.2%, leaving about 1,200 asthma patients unreviewed).
Early immunisations exceed 95.0% target before age-five dip.
At 24 months, 6-in-1 (96.7%) and MMR1 (95.6%) beat the 95.0% target, though age-five 4-in-1 booster (87.9%) and MMR2 (88.7%) fall below.
Population, age and ethnicity
Patients aged 65+ reach 23.0% alongside 70 care homes across the catchment
CISSBURY INTEGRATED CARE PCN has a registered population of 49,060 patients. Patients aged 65+ account for 23.0% (11,286 patients), compared with 22.1% in Worthing, 21.9% in NHS Sussex Integrated Care Board, and 17.9% in England. Those aged 18-64 represent 59.9% (Worthing 60.6%; NHS Sussex Integrated Care Board 60.5%; England 62.7%), while patients aged 0-17 comprise 17.1% (Worthing 17.4%; NHS Sussex Integrated Care Board 17.7%; England 19.6%). Census estimates record White ethnicity at 91.1% (England 81.1%), with an ethnic minority share of 8.9%.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Worthing local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Worthing LA) | 2,490 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 73.8% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 57.6% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Worthing LA) | 1,480 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Worthing LA) | 15.8 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 6.2% overall, concentrating heavily in two PCN practices
The PCN has an average IMD decile of 5.7, with 6.2% of registered patients in the Core20 cohort, above Worthing (4.4%) but below NHS Sussex Integrated Care Board (9.2%) and England (21.0%). Core20 patients concentrate in Strand Medical Group (7.83% share; 1,235 estimated patients) and Worthing Medical Group (7.39% share; 1,496 estimated patients), followed by Selden Medical Centre (3.57%; 322 estimated patients) and Cornerways Surgery (0.0%). Practice estimates sum to 3,053 patients compared with 2,895 estimated residents across 3 decile-2 LSOAs, reflecting differing population bases.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
788
SMI register
1.58% recorded prevalence
329
Learning disability register
0.66% recorded prevalence
70
Care homes, 1,781 beds
In the PCN catchment
9.0%
Provide unpaid care
Worthing, Census 2021
Recorded severe mental illness includes 788 patients (1.6% vs England 1.0%), and learning disability includes 329 patients (0.7% vs England 0.6%), representing 49.2% and 38.6% of Worthing's registers respectively, alongside 70 catchment care homes (1,781 beds, occupancy unconfirmed). Recorded SMI and learning disability prevalence above England may indicate high local support requirements across primary care.
Severe mental illness: physical health checks
Severe mental illness prevalence is 1.6% (England 1.0%). Over 2023 to 2025, BMI recording fell 1.0 pp to 79.9% (England +5.1 pp) and alcohol checks fell 3.5 pp to 76.2% (England +5.4 pp), with Strand Medical Group at 65.5% for.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
8,485
Hypertension register
+1.97%
Register growth, 3 yrs
Worthing +3.32% · England +5.60%
+5.35pp
BP control, under 80
≤140/90 · −0.62pp aged 80+
+542
More patients by 2030
Forecast 9,027 (17.73%)
Hypertension case-finding and control
Hypertension prevalence is 17.1% (8,485 patients), above England (15.2%) and NHS Sussex Integrated Care Board (16.3%) though below Worthing (17.4%). While 90.2% had a recent blood pressure check, treated-to-target achievement is 65.2% (Worthing 66.0%, England 70.3%). Blood pressure control in patients aged 80 and over is 73.4% (England 81.2%), falling 0.8% over 2023 to 2025 (England +2.2%). Control for patients aged under 80 reached 64.5% after +9.1% growth over 2023 to 2025 (England +3.2%), trailing England (67.8%). Lagging blood pressure control among older patients suggests scope to review treatment regimens.
Lipids and statins
Despite +11.7% growth over 2023 to 2025 (England +6.2%), lipid-lowering therapy for QRISK ≥ 20% patients is 53.8%, trailing Worthing (57.8%) and England (63.6%). Statin treatment for patients with diabetes and cardiovascular disease is 76.3% (Worthing 79.3%, England 84.4%). Lower uptake than national benchmarks suggests potential to recall eligible patients for lipid therapy.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 96,021 | £2.10 | £2.42 | £1.86 | £201,644 |
| Cardiovascular (all), 2025 | 132,372 | £2.81 | £3.32 | £3.33 | £371,965 |
In 2026, the PCN prescribed 96,021 lipid-regulating items at £2.10 per item (Worthing 2.24 gbp, England 1.86 gbp). Across 96,021 items, the PCN spends £23,045 more than at England's unit cost, and £30,727 less than at NHS Sussex Integrated Care Board's unit cost. Unit cost differences reflect prescribing mix rather than demonstrated inefficiency.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−1.23%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.06%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.7% (3,651 patients; England 6.6%), with prescribing of 1,679 items per 1,000 aged 5-19 (England 1,488). Annual asthma reviews fell 1.2% over 2023 to 2025 (England +4.4%) to 67.0%, leaving about 1,200 patients without a recorded review, with Worthing Medical Group at 59.5%. COPD prevalence is 1.8% (905 patients; England 1.9%), where reviews fell 1.6% over 2023 to 2025 (England +2.8%) to 78.1%. Review shortfalls indicate opportunities to expand routine respiratory review capacity across practices.
Cancer register and children's immunisation
Cancer prevalence is 4.9% (2,418 patients; England 3.8%). In Q1 2025/26, childhood vaccination exceeds the 95.0% target at 24 months (96.7% for 6-in-1, 95.6% for MMR dose 1). At age 5, coverage falls below the 95.0% target by 7.1 pp for the 4-in-1 booster (87.9%) and by 6.3 pp for MMR dose 2 (88.7%), with a 4 pp difference between doses.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
Across NHS Sussex ICB in 2022, 58.5% of staged cancers (4,799 of 8,209) were diagnosed at stage 1 or 2, above England (55.3%) but 16.5 pp below the 75.0% national ambition. Known-stage share was 64.3% (8,209 of 12,766), trailing England (67.0%). For CISSBURY INTEGRATED CARE PCN, cancer prevalence is 4.9% (2,418 patients; England 3.8%), while cervical screening is 69.4% (England 66.8%) but reaches 60.3% at Selden Medical Centre. Staging reflects ICB-level data rather than PCN performance, and incomplete staging coverage or small site cohorts limit direct conclusions. Screening variations across member practices may contribute to missed opportunities for early detection before specialist referral.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, University Hospitals Sussex NHS Foundation Trust achieved 65.2% on the 62-day referral to treatment cancer standard, trailing East Sussex Healthcare NHS Trust (67.0%), Surrey and Sussex Healthcare NHS Trust (70.0%), NHS Surrey and Sussex Integrated Care Board (71.5%) and England (71.2%), standing 19.8 pp below the 85.0% standard. Diagnostic 6-week waits reached 12.9% overall (England 23.1%), but lower gastrointestinal endoscopy saw longer waits, with colonoscopy 6-week waits at 39.3% (England 30.8%) and flexible sigmoidoscopy at 45.4% (England 32.1%). Secondary care treatment backlogs and endoscopy delays could lengthen diagnostic pathways for urgent cancer referrals.
| Pathways within standard (%) | Sussex | East Sussex Healthcare | Surrey and Sussex Healthcare | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 74.01 | 84.20 | 77.74 | 79.29 | 79.32 |
| 31-day treatment (96%) | 76.79 | 98.19 | 96.20 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 65.20 | 67.04 | 69.97 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Sussex | East Sussex Healthcare | Surrey and Sussex Healthcare | England |
|---|---|---|---|---|
| MRI | 5.62 | 6.48 | 27.53 | 21.40 |
| CT | 8.57 | 0.48 | 18.49 | 9.92 |
| Echocardiography | 0.39 | 21.94 | 43.78 | 28.48 |
| Colonoscopy | 39.35 | 0.74 | 15.11 | 30.83 |
| Gastroscopy | 20.02 | 0.31 | 21.06 | 29.02 |
| All 15 DM01 tests | 12.95 | 5.27 | 28.50 | 23.14 |
| Community services activity | West Sussex residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 78,050 | 309,615 |
| Referrals | 16,015 | 66,930 |
| Patients with a contact | 19,770 | 85,660 |
Community services (residents of West Sussex), Jun 2026 (provisional). In June 2026, provisional community services data shows 72.7% of all contacts for Worthing borough residents (56,740 of 78,050 contacts) were with adults aged 65 and over. These figures reflect upper-tier borough resident activity rather than PCN-specific contacts. High community contact volumes among older residents underline substantial local demand for intermediate and rehabilitative support.
Practice variation and patient experience
Practice phone access varies by 54.2 pp and vaccination achievement by 56.5 pp
QOF overall achievement ranges from 92.2% at Selden Medical Centre to 98.8% at Cornerways Surgery (England 92.5%). While clinical domain scores exceed 97.0% across all practices (Worthing Medical Group 97.0%; Cornerways Surgery 100.0%), vaccination achievement spans 56.5 pp, from 33.2% at Selden Medical Centre to 89.8% at Cornerways Surgery (England 55.2%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Cornerways Surgery | 119 | 0.0 | 96.2% | 77.6% | 96.9% |
| Selden | 98 | 3.6 | 81.5% | 78.7% | 95.7% |
| Worthing Medical | 117 | 7.4 | 42.0% | 65.0% | 82.8% |
| Strand Medical | 117 | 7.8 | 62.0% | 66.1% | 77.5% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Sixteen of 25 measures lagged national three-year changes despite strong blood pressure gains
Between 2023 and 2025, 16 of 25 compared measures trailed England's three-year change. Reviews and health checks lagged national trends, led by heart failure reviews (-2.3% vs England +8.7%), psychosis alcohol recording (-3.5 pp vs England +5.4 pp), and mental health BMI checks (-1.0 pp vs England +5.1 pp), alongside COPD (-1.6% vs England +2.8%) and asthma reviews (-1.2% vs England +4.4%). Conversely, under-80 blood pressure control (+9.1% vs England +3.2%) and QRISK ≥ 20% lipid therapy (+11.7% vs England +6.2%) outpaced national gains.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Alcohol record (psychosis)
BMI record (SMI)
Asthma reviews
COPD reviews
BP control, under 80
QRISK statin treatment
Diabetes statin (no CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Worthing | Asset | PCN | Worthing |
|---|---|---|---|---|---|
| Care homes (catchment) | 70 (1,781 beds) | n/a | Schools (catchment) | 51 | n/a |
| Children's centres | 5 | 7 | Places of worship | 42 | 48 |
| Libraries | 5 | 5 | Homelessness support (VCS) | 0 | no data |
| Day centres (VCS) | 1 | 1 | Carers support groups (VCS) | 1 | 1 |
| Primary schools (LA maintained) | 11 | 13 | Primary academies | 8 | 8 |
| Special schools | 1 | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
Annual asthma reviews fell 1.2% (-0.8 pp) over 2023 to 2025 (England +4.4%) to 67.0% (Worthing Medical Group 59.5%), leaving an estimated 1,205 (about 1,200) of 3,651 patients unreviewed. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
CVD lipid and hypertension escalation
Across 8,485 hypertension patients (17.1%, modelled gap -1,013 to +67), BP control is 65.2% (England 70.3%) and 73.4% in aged 80+ (England 81.2%). QRISK ≥ 20% lipid therapy is 53.8% (England 63.6%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Pre-school booster and MMR2 catch-up
In Q1 2025/26 (cohort 124), age-5 coverage trails the 95.0% target by 7.1 pp for 4-in-1 (87.9%) and 6.3 pp for MMR2 (88.7%, 4 pp below MMR1 at 92.7%), while QOF vaccination spans 56.5 pp. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Anticipatory frailty reviews (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check outreach (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Older hypertensive medication review (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Preschool booster recall catchup (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening uptake outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice telephony and access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN & Practice |
| Option 2 · CVD lipid and hypertension escalation (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Pre-school booster and MMR2 catch-up (p12) | Asthma register · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 · MMR dose 2 coverage at age 5 | Core20PLUS5 respiratory | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
